Skip to main content
. Author manuscript; available in PMC: 2015 Jul 1.
Published in final edited form as: J Pediatr Hematol Oncol. 2014 Jul;36(5):353–361. doi: 10.1097/MPH.0000000000000131

Figure 2.

Figure 2

Figure 2

Figure 2a. DFS for MTX comparison: AB vs. CD (n=784)

The 5-year DFS for patients who received Regimens A/B (standard dose of MTX at 1 gm/m2) was 71.8 ± 2.4% versus 71.7 ± 2.4% for patients who received Regimens C/D (the higher dose of MTX at 2.5 gm/m2).

Figure 2b. DFS for AraC comparison: AC vs. BD (n=784)

The 5-year DFS for patients who received Regimens A/C (ara-C/teniposide) was 70.4 ± 2.4% versus 73.1 ± 2.3% for patients who received Regimens B/D (HD ara-C/asparaginase).